Fate Uncertain As Cell Therapy Biotech Pulls Out Of J&J Deal, Restructures
The company is discontinuing its lead clinical programs and planning major layoffs as it seeks to reprioritize its pipeline and extend cash runway.
You may also be interested in...
Allogeneic candidate’s durability is holding up thanks to a novel conditioning regimen, but Phase II data will be crucial test.
A new collaboration with Cellular Biomedicine includes a CD19/CD20-directed bispecific CAR-T in Phase I development for B-cell non-Hodgkin lymphomas.
As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.